Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott’s Humira gets another EU OK
Ankylosing spondylitis (AS) is a chronic disease of the axial skeleton and large peripheral joints that causes inflammatory back pain and stiffness, but is also associated with other
Ankylosing spondylitis (AS) is a chronic disease of the axial skeleton and large peripheral joints that causes inflammatory back pain and stiffness, but is also associated with other
The funds will be used to complete preclinical development of the vaccine and file an investigational new drug application (IND) with the FDA, which would allow initiation of
Celltrion will perform bioprocess development, scale-up, and cGMP manufacturing and provide all clinical materials to support toxicology studies as well as phase I and phase II US clinical
The open label, single-agent study will be conducted at two centers with well known expertise in developing new oncology drugs: the Barbara Ann Karmanos Cancer Institute in Detroit,
Abraxane was approved in the US for metastatic breast cancer in January 2005 but only for use after combination chemotherapy treatments had failed. This Canadian approval is the
PRX-07034 is the fourth novel drug candidate from Preix’ drug discovery platform to progress into human clinical trials. It is a novel, highly selective, small-molecule antagonist of a
INCB13739 is an orally available small molecule inhibitor of 11-beta hydroxysteroid dehydrogenase type 1 (11beta-HSD1), an enzyme that appears to be critical to the development of type 2
The discovery by researchers in Hopkins’ Institute of Basic Biomedical Sciences and McKusick-Nathans Institute for Genetic Medicine reveals that a protein called GCN5 is critical for controlling a
In preclinical models, a new formulation of the angiotensin vaccine containing CoVaccine’s adjuvant resulted in a tenfold higher level of antibody production against angiotensin than the formulation previously
The study evaluated treatment of about 300 patients who had severe chronic heart failure despite traditional treatment. They were studied in three groups, two of which were treated